Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525330 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone
A Phase 2 study of Type 2 Diabetes, sponsored by ActivX Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
- 1
- Study location
NCT00525330: Completed Phase 2 study of Type 2 Diabetes, sponsored by ActivX Biosciences.
NCT00525330 is a Phase 2 study of Type 2 Diabetes that has completed, run by ActivX Biosciences. The registered enrollment target is 213 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00525330, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by ActivX Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the safety and efficacy of chronic therapy with KRP-104, a novel DPP-IV inhibitor, in patients with Type 2 Diabetes on stable metformin therapy. In addition, an estimate of how much of the HbA1c response is attributable to nocturnal coverage will be explored.
Conditions Studied
Interventions
- DRUG KRP-104 QD Drug: Placebo Drug: Metformin
- DRUG Placebo Drug: Metformin
- DRUG KRP-104 BID Drug: Placebo Drug: Metformin
Study Locations (1)
California
- - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
What the finished NCT00525330 record still lists
NCT00525330 is an interventional study that assigns participants to a tested intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which KRP-104 QD Drug: Placebo Drug: Metformin is the first listed.
NCT00525330 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00525330 about?
NCT00525330 is a clinical study titled "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone". To assess the safety and efficacy of chronic therapy with KRP-104, a novel DPP-IV inhibitor, in patients with Type 2 Diabetes on stable metformin therapy. In addition, an estimate of how much of the HbA1c response is attributable to nocturnal coverage will be explored.
What is the current status of trial NCT00525330?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2007-09. Estimated completion is 2008-08.
What conditions does trial NCT00525330 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00525330?
The interventions under investigation include: KRP-104 QD Drug: Placebo Drug: Metformin (DRUG), Placebo Drug: Metformin (DRUG), KRP-104 BID Drug: Placebo Drug: Metformin (DRUG).
Who is sponsoring clinical trial NCT00525330?
This trial is sponsored by ActivX Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00525330 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00525330's enrollment target sits among peer trials
213 92nd of 327 higher than 236 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RECRUITING · Phase 2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
RECRUITING · Phase 2
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RECRUITING · Phase 2
-
NAD Augmentation in Diabetes Kidney Disease
RECRUITING · Phase 2
-
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia